Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-071 · 1 trial · 2 indications
Stride time (or gait) is defined as the time elapsed between the first contact of two consecutive footsteps of the same foot and is expressed in seconds. The standard deviation (SD) of the stride time, recorded for each foot during the 2-minutes, is averaged to obtain stride time (gait) variability. The 2-minute walk was performed with and without simultaneous performance of serial 3 subtraction, which adds a cognitive load to the task. Data are reported with and without cognitive load.
| Arm | Type | Description |
|---|---|---|
| Placebo + TAK-071 (PD Participants) | EXPERIMENTAL | TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2. |
| TAK-071 + Placebo (PD Participants) | EXPERIMENTAL | TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2. |
| Sentinel Cohort: Placebo (Healthy Participants) | EXPERIMENTAL | A single dose of TAK-071 placebo-matching mg, tablet, orally, on Day 1. |
| Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants) | EXPERIMENTAL | A single dose of TAK-071 ≤ 7.5 milligrams (mg), tablet, orally, on Day 1. |
| Name | Type | Description |
|---|---|---|
| TAK-071 | DRUG | TAK-071 tablet. |
| Placebo | DRUG | TAK-071 placebo-matching tablet. |
Key Inclusion Criteria: 1. Is an outpatient of any sex aged between 40 and ≤ 85 years, inclusive, at the time of consent. 2. Has a diagnosis of PD according to Movement Disorders Society (MDS) clinical diagnostic criteria for PD. Participants with DLB (i.e., dementia diagnosed before onset of motor...
TAK-071 is an investigational small molecule being studied for the treatment of Parkinson Disease. It is a Phase 2 drug candidate developed by Takeda Pharmaceutical Company Limited. The drug is being evaluated in a clinical trial involving participants with Parkinson Disease and healthy participants.
TAK-071 is a small molecule being developed for Parkinson Disease. Its specific molecular target has not been disclosed in the available information. The drug is being studied for its potential effects in people with Parkinson Disease, though the exact mechanism of action is not publicly detailed.
TAK-071 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research on this investigational drug for Parkinson Disease. TAK-071 is currently in Phase 2 development.
TAK-071 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for Parkinson Disease, and one Phase 2 trial has been completed.
TAK-071 has been studied in a Phase 2 clinical trial with the identifier NCT04334317. This trial, titled "A Study of TAK-071 in People With Parkinson Disease," was conducted in the United States and enrolled 64 participants. The trial included both people with Parkinson Disease and healthy participants.
TAK-071 is the primary name for this investigational drug candidate. No alternative names have been reported for this compound. It is being developed by Takeda Pharmaceutical Company Limited for the treatment of Parkinson Disease.